A psychonaut is someone who deliberately explores altered states of consciousness, typically to gain self-knowledge, spiritual insight, or a deeper understanding of the mind. The term was coined by German writer Ernst Jünger in 1970 and literally means “sailors of the soul.” While many people associate psychonauts with psychedelic drug use, the practice also encompasses non-drug techniques like meditation, breathwork, sensory deprivation, and lucid dreaming.
Where the Term Comes From
Jünger used “psychonaut” in a 1970 article about his own psychedelic experiences, specifically to describe Arthur Heffter, the German chemist who first isolated mescaline in the 1890s. The word combines the Greek “psyche” (soul or mind) with “nautes” (sailor or navigator), framing the practice as a kind of inner voyage. That metaphor stuck. Today it describes a loose, global subculture of people who treat consciousness exploration as a serious pursuit rather than casual recreation.
What Makes It Different From Recreational Drug Use
The key distinction is intention. A psychonaut approaches altered states with specific goals: investigating how their own mind works, seeking spiritual experiences, or gathering insights they can apply to daily life. Researchers have formally defined a psychonaut as “a scientific explorer of inner space,” someone trained to observe and report on their subjective experience with the same rigor a field researcher would bring to studying an unfamiliar environment.
That intentional framing shapes the entire experience. Psychonauts often keep detailed journals, plan their sessions carefully, and spend significant time afterward processing what happened. The recreational user and the psychonaut might use the same substance, but the relationship to the experience is fundamentally different.
Methods Beyond Psychedelics
Psychedelics get the most attention, but psychonauts use a wide range of techniques to reach altered states. These include meditation, hypnosis, sensory deprivation (float tanks), brainwave entrainment, and lucid dreaming. One increasingly studied method is high ventilation breathwork, which involves breathing deeply without pausing, usually while listening to music that builds in tempo and intensity. Research from the British Psychological Society has found this technique can induce psychedelic-like states without any substance use at all.
Many psychonauts combine approaches. Someone might maintain a daily meditation practice while occasionally using psychedelics for deeper exploration, or alternate between float tank sessions and breathwork. The common thread is the deliberate induction of non-ordinary consciousness for the purpose of self-investigation.
What Happens in the Brain
Neuroscience has started to explain why these experiences feel so profound. Classical psychedelics like psilocybin, LSD, and ayahuasca all disrupt a brain network called the default mode network, which is active during ordinary waking consciousness and plays a central role in your sense of self, your mental habits, and the running narrative in your head.
Under the influence of psychedelics, connectivity within this network drops sharply while connections between brain regions that don’t normally communicate increase dramatically. The brain shifts from a modular, compartmentalized state to a more globally interconnected one. A systematic review in the International Journal of Neuropsychopharmacology found this pattern is remarkably consistent across different psychedelics. Psilocybin, LSD, and ayahuasca all produce the same signature: less internal chatter in the self-referential network, more crosstalk everywhere else. Researchers have described the result as “a mind that is less constrained, more flexible, and less self-referential.”
This is likely why psychonauts report experiences of ego dissolution, feelings of interconnectedness, and the sense that rigid thought patterns have temporarily loosened. The brain is, for a window of time, literally operating in a less siloed way.
Common Substances
The most widely used psychonautic substances are psilocybin (found in certain mushrooms), LSD, DMT, and ayahuasca (a plant brew containing DMT). Each has a different duration and character. DMT administered intravenously produces effects within two minutes that peak around five to ten minutes and fully resolve within 30 minutes, making it one of the shortest psychedelic experiences. Psilocybin and LSD, taken orally, have a slower onset and last several hours. Ayahuasca, also taken orally, typically produces a longer experience as well.
The substance matters less to the psychonaut than the quality of the exploration it enables. Many psychonauts develop preferences based on what type of inner work they’re pursuing and how much time they have available.
Set, Setting, and Harm Reduction
The concepts of “set” and “setting” are foundational to psychonautic practice. “Set” refers to your mindset going in: your emotional state, expectations, intentions, and psychological history. “Setting” refers to the physical and social environment, including who you’re with, where you are, and what the atmosphere feels like. Research consistently shows these two factors have an enormous influence on whether a psychedelic experience is positive and productive or frightening and destabilizing.
Experienced psychonauts treat preparation as seriously as the experience itself. This typically means choosing a safe, comfortable environment, having a trusted sober companion present, setting clear intentions beforehand, and avoiding altered states during periods of emotional instability or mental health crisis.
Integration: Making Sense of the Experience
What separates psychonautic practice from simply “tripping” is what happens afterward. Integration is the process of making sense of an altered state experience and applying its insights to everyday life. Mental health professionals who work with psychedelic integration typically use a two-stage model. The early stage focuses on basic support, stabilization, and simply describing what happened in a safe, non-judgmental space. Some therapists have clients draw a timeline of the experience or map their emotional intensity over time to organize what can feel like an overwhelming flood of information.
The later stage goes deeper, exploring the specific content of the experience and working to incorporate key insights into lasting behavioral changes. Without this step, even the most powerful experience tends to fade into a vivid memory rather than producing real growth. Psychonauts often describe integration as the hardest and most important part of the practice.
Risks and Psychological Safety
Psychonautic exploration carries real risks, particularly when psychedelics are involved. One recognized condition is hallucinogen persisting perception disorder (HPPD), in which visual disturbances from a psychedelic experience continue long after the substance has left the body. Estimates suggest HPPD affects roughly 4% to 4.5% of people with a history of hallucinogen use. Symptoms can include visual snow, trailing images, or halos around objects, and they can cause significant distress in daily life.
Beyond HPPD, psychedelics can trigger acute psychological distress during the experience itself, and in rare cases, they can precipitate lasting mental health issues in people with a predisposition to conditions like psychosis. This is one reason the psychonaut community places such heavy emphasis on preparation, set and setting, and careful dose selection.
The Legal Landscape
Most psychedelic substances remain illegal in the majority of jurisdictions, but the legal picture is shifting. In the United States, several cities have made enforcement against entheogenic plants and fungi their lowest law enforcement priority. In California, Oakland, Santa Cruz, Arcata, Berkeley, and San Francisco have all passed such resolutions. In Michigan, Ann Arbor, Detroit, Hazel Park, Ypsilanti, and Washtenaw County have taken similar steps. Oregon became the first state to create a regulated framework for psilocybin services.
This evolving legal status reflects growing clinical interest. Phase 2 clinical trials for psilocybin-assisted therapy in major depression have shown response rates (a 50% or greater reduction in symptom severity) ranging from 37% to 70%, with remission rates between 29% and 57% depending on the trial and dosing protocol. These results are driving both scientific attention and policy changes, though full legalization remains uncommon.